Shire latched onto the rare disease drugs trend years before bigger rivals. Photographer: JB Reed/Bloomberg

London-listed Shire is buying ViroPharma for $4.2 billion its biggest deal yet to strengthen its portfolio of lucrative drugs to treat rare diseases, (...)